Prostate Cancer (PCa) screening using Prostate-Specific Antigen (PSA) has significantly improved early detection but has also led to substantial overdiagnosis and overtreatment, particularly of indolent tumors. This evidence concerns the gene KLK3 and Familial prostate cancer.